

## REMARKS

Claims 125-201 are pending.

The present application is a divisional of application serial No. 10/076,571, now allowed.

Formula (A) and (B) at pages 6 and 16 of the specification, respectively, have been amended to correct the number of R<sup>6</sup> groups. As described in the specification, there is one R<sup>5</sup> group attached to the ring defined by the Qs. Three of the Qs may be a nitrogen atom. Therefore, the minimum number of R<sup>6</sup> groups is 1 (when 3 Qs are nitrogen atoms) and the maximum number of R<sup>6</sup> groups is 4 (when none of the Qs are nitrogen atoms). Formula (A) and (B) have been amended to correctly show 1-4 R<sup>6</sup> groups. In addition, a revised Abstract has been submitted to make the corresponding change to formula (A).


Claim 125 has been amended to specify 2 R<sup>6</sup> groups in view of the remarks above, since two Qs are nitrogen atoms. Claim 199 has been amended to specify a P2Y2 receptor agonist, which is described in the specification at page 23, line 21.

No new matter is believed to have been added to this application by the amendments submitted above.

Applicants submit that the present application is ready for examination on the merits. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



---

James J. Kelly, Ph.D.  
Registration No. 41,504

Customer Number

**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
JK/cja